Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Is The Projected Market Size Of The Semi-Solid Dosage Contract Manufacturing Market By 2029?
The semi-solid dosage contract manufacturing market has experienced rapid expansion in its size over recent years. Projections indicate it will increase from $16.23 billion in 2024 to $17.97 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.7%. This historical growth is attributable to several factors, including the expanding geriatric population, rising global healthcare spending, a significant increase in demand for hormone replacement therapies, enhanced awareness regarding skincare health, and the development of biologics and biosimilars in topical applications.
The semi-solid dosage contract manufacturing market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $26.76 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.5%. This anticipated growth during the forecast timeframe stems from factors such as increased demand for dermatological therapies, a growing incidence of persistent skin ailments, the expansion of generic pharmaceutical output, the cost-effectiveness offered by contract manufacturing, and the escalating need for topical drug administration. Key trends shaping the market over the forecast period encompass innovations in formulation techniques, a requirement for adaptable production capabilities, the integration of quality-by-design methodologies, technological improvements in equipment for semi-solid processing, and the imperative for accelerated drug development.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25899&type=smp
What Are The Main Drivers Boosting The Semi-Solid Dosage Contract Manufacturing Industry’s Expansion?
A significant occurrence of skin conditions is projected to boost the expansion of the semi-solid dosage contract manufacturing market in the future. Skin diseases are defined as ailments impacting the skin’s look or operation, frequently leading to signs like discomfort, swelling, or unusual growths on the skin. The incidence of skin diseases is increasing because of growing environmental contamination, which compromises the skin’s protective barriers, resulting in heightened sensitivity, allergic responses, and ongoing dermatological issues. Through the provision of top-tier, consistently formulated topical remedies, contract manufacturing of semi-solid dosage forms contributes to the prevention of skin diseases by effectively preserving and enhancing skin well-being. For example, data from Cancer Research UK, a UK-based cancer research body, indicated in February 2023 that the average annual occurrence of melanoma skin cancer in the UK is predicted to rise from approximately 20,800 cases between 2023–2025 to roughly 26,500 cases by 2038–2040. Consequently, the widespread occurrence of skin conditions is a key factor propelling the expansion of the semi-solid dosage contract manufacturing market.
Which Key Segments Fueling The Semi-Solid Dosage Contract Manufacturing Market?
The semi-solid dosage contract manufacturing market covered in this report is segmented –
1) By Type: Topical, Transdermal, Oral
2) By Material Type: Synthetic, Natural, Bio-Based
3) By Company Size: Large Size Companies, Medium And Small Size Companies, Other Company Sizes
4) By Therapeutic Application: Dermatology, Pain Management, Hormonal Therapy, Wound Care, Ophthalmic Disorders, Other Therapeutic Applications
5) By End Use: Pharmaceutical Companies, Cosmeceutical Companies, Other End Uses
Subsegments:
1) By Topical: Creams, Ointments, Gels, Lotions, Pastes, Foams
2) By Transdermal: Transdermal Gels, Transdermal Creams, Transdermal Sprays, Transdermal Emulsions, Medicated Patches
3) By Oral: Oral Gels, Oral Pastes, Oral Suspensions, Oral Emulsions, Oral Jellies
What Trends Are Redefining The Semi-Solid Dosage Contract Manufacturing Market Dynamics?
Prominent companies operating within the semi-solid dosage contract manufacturing market are concentrating on strategic investments to open up new markets and encourage innovation. Strategic investments are defined as long-term financial commitments made to support and reinforce a company’s primary objectives, future growth, or its competitive standing in the market. For instance, in March 2025, LGM Pharma, a US-based provider of semi-solid dosage contract manufacturing services, declared an investment exceeding $6 million to expand its manufacturing facility located in Rosenberg, Texas. The purpose of this investment is to increase production capacity for liquid, suspension, semi-solid, and suppository drug formulations, thereby meeting the escalating demand for domestic pharmaceutical manufacturing. This initiative is consistent with LGM Pharma’s ongoing expansion in prescription drug development, which includes 505(b)(2) and ANDA programs. The improvements at the Rosenberg site will facilitate greater output while guaranteeing full compliance with FDA requirements and current good manufacturing practices. The facility is set to maintain continuous operation during the expansion phase.
Which Leading Companies Dominate The Semi-Solid Dosage Contract Manufacturing Market Share?
Major companies operating in the semi-solid dosage contract manufacturing market are Eurofins Scientific SE, The Lubrizol Corporation, Grunenthal, Recipharm AB, Piramal Pharma Solutions Inc., Cambrex Corporation, Sharp Services, ANI Pharmaceuticals, Pierre Fabre SA, Aurigene Pharmaceutical Services Limited, DPT Laboratories Ltd., Douglas Pharmaceuticals Ltd., Mission Pharmacal Co., Pace Analytical Life Sciences LLC, Bora Pharmaceuticals Co. Ltd., Ascendia Pharmaceuticals Inc., Fermion Oy, Ferndale Pharma Group, Sterling Pharmaceutical Services LLC, Aphena Pharma Solutions Inc., Eubioco LLC, LGM Pharma LLC, Madras Pharmaceuticals, Quality CDMO, Axxelent Pharma Science.
Download The Full Report For Exclusive Market Findings:
What Regional Growth Trends Are Shaping The Semi-Solid Dosage Contract Manufacturing Market Outlook?
North America was the largest region in the semi-solid dosage contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the semi-solid dosage contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Semi-Solid Dosage Contract Manufacturing Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25899&type=smp
Browse Through More Reports Similar to the Global Semi-Solid Dosage Contract Manufacturing Market 2025, By The Business Research Company
Oral Solid Dosage Contract Manufacturing Global Market Report 2025
Oral Solid Dosage Pharmaceutical Formulation Global Market Report 2025
Fill Finish Pharmaceutical Contract Manufacturing Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model